Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547590 | 0.86 | MAPT (0.48) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL14134198 | 0.86 | MAPT (0.48) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL27097180 | 0.86 | WNT3A (0.45) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL20128557 | 0.86 | CYP11B2 (0.47) | CHEK1CYP11B2 | |
| SCHEMBL22906722 | 0.85 | NPC1 (0.44) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL20128566 | 0.85 | NPC1 (0.43) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL27097179 | 0.84 | TOP2A (0.43) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL27097181 | 0.84 | GRIN2B (0.39) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL27097256 | 0.83 | NPC1 (0.41) | NPC1POLBGAARAB9ARXFP1 | |
| SCHEMBL29547444 | 0.82 | METAP2 (0.47) | NPC1POLBGAARAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | NPC1 2550/4885POLB 2944/4885GAA 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.